Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 141.

https://doi.org/10.1182/blood-2019-122907

Published: 2019

Journal Articles

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Blood (2019) 134 (Supplement_1): 3140.

https://doi.org/10.1182/blood-2019-129038

Published: 2019

Journal Articles

Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Christine I Chen, MD, Heather J. Sutherland, MD PhD, Rami Kotb, MD, Michael Sebag, MD PhD, Darrell J. White, MD, William Bensinger, MD, Cristina J Gasparetto, MD, Richard Leblanc, MDFRCPC, Christopher P. Venner, MD FRCPC, Suzanne Lentzsch, MD, Gary J. Schiller, MD, Brea Lipe, MD, Aldo Del Col, Jatin J. Shah, MD, Jacqueline Jeha, Jean-Richard Saint-Martin, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2018-99-117349

Published: 2018

Journal Articles

A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Darrell J White, MD, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Gary J Schiller, MD, Cristina J. Gasparetto, MD, Heather J. Sutherland, MD PhD FRCPC, Michael Sebag, MD PhD, Suzanne Lentzsch, MD PhD, Rami Kotb, MD, William Bensinger, MD, Brea C. Lipe, MD, Christine I Chen, MD FRCP(C), Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD, Richard LeBlanc, MDFRCPC

Blood (2017) 130 (Supplement 1): 1861.

https://doi.org/10.1182/blood.V130.Suppl_1.1861.1861

Published: 2017

Journal Articles

Next Generation Sequencing of Castleman Disease and Follicular Dendritic Cell Sarcomas Associated with Castleman Disease

Alexandra Nagy, MD, Aparna Bhaduri, Nahid Shahmarvand, MD, Jahanbanoo Shahryari, MD, James L. Zehnder, MD, Roger Warnke, MD, Tariq I Mughal, MD FRCP, Siraj M Ali, MD PhD, Robert S. Ohgami, MD PhD

Blood (2017) 130 (Supplement 1): 4016.

https://doi.org/10.1182/blood.V130.Suppl_1.4016.4016

Published: 2017

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

Robert Frank Cornell, MD, Adriana C. Rossi, MDMSc, Rachid Baz, MD, Craig C Hofmeister, MDMPH, Chaim Shustik, MD, Joshua R Richter, MD, Christine I Chen, MD FRCP(C), Dan T. Vogl, MD, Erkan Baloglu, William Senapedis, PhD, Joel Ellis, PhD, Tony Williams, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2017) 130 (Supplement 1): 3134.

https://doi.org/10.1182/blood.V130.Suppl_1.3134.3134

Published: 2017

Journal Articles

Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure

Christine I Chen, MD FRCP(C), Heather J. Sutherland, MD PhD FRCPC, Rami Kotb, MD, Michael Sebag, MD PhD, Darrell J White, MD, William Bensinger, MD, Cristina J. Gasparetto, MD, Richard LeBlanc, MDFRCPC, Christopher P. Venner, MD, Suzanne Lentzsch, MD PhD, Gary J. Schiller, Brea C. Lipe, MD, Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 3136.

https://doi.org/10.1182/blood.V130.Suppl_1.3136.3136

Published: 2017

Journal Articles

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Trinayan Kashyap, MS, Irfana Muqbil, Amro Aboukameel, Boris Klebanov, MA, MS, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, William Senapedis, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 4131.

https://doi.org/10.1182/blood.V128.22.4131.4131

Published: 2016

Journal Articles

Nek2 Stabilization By Usp7 Leads to Activation of NF-Kb in Multiple Myeloma

Reinaldo Franqui Machin, BS, Xin Zhan, BA, Hongwei Xu, DDS, Ivana Frech, DSc, PhD MBA, Guido J Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2016) 128 (22): 4418.

https://doi.org/10.1182/blood.V128.22.4418.4418

Published: 2016

Journal Articles

LIGHT (TNFSF14) Increases Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells Via LTβR

Hawk Kim, Sook-Kyoung Heo, PhD, Eui-Kyu Noh, PhD, Gi-Dong Gwon, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD PhD, Jinny Park

Blood (2016) 128 (22): 4546.

https://doi.org/10.1182/blood.V128.22.4546.4546

Published: 2016

Journal Articles

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Greg P Coffey, PhD, Jiajia Feng, MD, Sabah Kadri, PhD, Y. Lynn Wang, MD PhD, Pin Lu, PhD, Shruti Sharma, PhD, Jeremy Segal, PhD, Glenn Michelson, MD, Anjali Pandey, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 2768.

https://doi.org/10.1182/blood.V128.22.2768.2768

Published: 2016

Journal Articles

Mechanisms of Suppressive Effects of MYD88 Inhibitors on the Growth of Lymphoma and Leukemia Cells

Erika Shiratori, Mai Itoh, PhD, Mika Ohtaka, Shohei Nogami, Shuji Tohda, MD PhD

Blood (2016) 128 (22): 2773.

https://doi.org/10.1182/blood.V128.22.2773.2773

Published: 2016

Journal Articles

Cap Analysis of Gene Expression (CAGE) Sequencing Reveals Alterations of the Transcriptional Signatures of FLT3-ITD with Secondary D835 TKD Mutations in Acute Myeloid Leukemia

Yoko Tabe, MD PhD, Kazumasa Sekihara, PhD, Kaori Saitoh, Norikazu Monma, PhD, Kazuho Ikeo, PhD, Bogumil Kaczkowski, Weiguo Zhang, MD, PhD, Yasunari Yamanaka, MD PhD, Takashi Miida, MDPhD, Neil P. Shah, MD PhD, Hironori Harada, MD PhD, Yoshihide Hayashizaki, MD PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 1530.

https://doi.org/10.1182/blood.V128.22.1530.1530

Published: 2016

Journal Articles

Aberrant TNFAIP3 Induces Mesenchymal Stem Cell Impairment Via the NF-Kb/SMAD7 Signaling Pathway in Immune Thrombocytopenia

Yun He, Jia-Min Zhang, Lin-Lin Xu, Xiao-Lu Zhu, Qian Jiang, Hao Jiang, Jin Lu, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang

Blood (2016) 128 (22): 364.

https://doi.org/10.1182/blood.V128.22.364.364

Published: 2016

Journal Articles

Selective Death of Leukemia Initiating Cells Induced By Deferasirox

Saar Shapira, MSc, Pia Raanani, MD, Arnon Nagler, Ido Lubin, PhD, Nadir Arber, MD, Galit Granot, PhD

Blood (2016) 128 (22): 581.

https://doi.org/10.1182/blood.V128.22.581.581

Published: 2016

Journal Articles

Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia

Zachary A. Hing, BS, James S. Blachly, MD, Virginia M. Goettl, DVM, PhD, Guramrit Singh, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD

Blood (2016) 128 (22): 972.

https://doi.org/10.1182/blood.V128.22.972.972

Published: 2016

Journal Articles

Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance

Maria Todaro, PhD, Valentina Griggio, Ms, Candida Vitale, MD, Chiara Salvetti, MD, Chiara Riganti, MD, Mario Boccadoro, MD, Yosef Landesman, PhD, Marta Coscia, MD PhD

Blood (2016) 128 (22): 3210.

https://doi.org/10.1182/blood.V128.22.3210.3210

Published: 2016

Journal Articles

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Blood (2015) 126 (23): 258.

https://doi.org/10.1182/blood.V126.23.258.258

Published: 2015

Journal Articles

Microrna-17~92 Cluster Upregulates NF-KB Activity Via Suppressing Multiple NF-KB Negative Regulators Mediating Ubiquitination

Xianhuo Wang, MD, Huaqing Wang, Chengfeng Bi, Xiaoyan Zhang, Xin Huang, Xuan Zhang, Javeed Iqbal, George W Wright, Louis M Staudt, Wing C Chan, Timothy W McKeithan, Ping Wang, Huilai Zhang, Kai Fu, MD PhD

Blood (2015) 126 (23): 3638.

https://doi.org/10.1182/blood.V126.23.3638.3638

Published: 2015

Journal Articles

Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma

Maciej Szydlowski, PhD, Monika Prochorec-Sobieszek, MD PhD, Anna Szumera-Cieckiewicz, MD PhD, Grazyna Hoser, PhD, Ewa Jablonska, PhD, Emilia Bialopiotrowicz, PhD, Przemyslaw Kiliszek, MSc, Tomasz Sewastianik, MSc, Anna Polak, MSc, Wojciech Czardybon, PhD, Michal Galezowski, PhD, Renata Windak, PhD, Krzysztof Brzozka, PhD, Krzysztof Warzocha, MD PhD, Jan Maciej Zaucha, MD PhD, Przemyslaw Juszczynski, MD PhD

Blood (2015) 126 (23): 819.

https://doi.org/10.1182/blood.V126.23.819.819

Published: 2015

NARROW

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Next Generation Sequencing of Castleman Disease and Follicular Dendritic Cell Sarcomas Associated with Castleman Disease

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Nek2 Stabilization By Usp7 Leads to Activation of NF-Kb in Multiple Myeloma

LIGHT (TNFSF14) Increases Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells Via LTβR

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Mechanisms of Suppressive Effects of MYD88 Inhibitors on the Growth of Lymphoma and Leukemia Cells

Cap Analysis of Gene Expression (CAGE) Sequencing Reveals Alterations of the Transcriptional Signatures of FLT3-ITD with Secondary D835 TKD Mutations in Acute Myeloid Leukemia

Aberrant TNFAIP3 Induces Mesenchymal Stem Cell Impairment Via the NF-Kb/SMAD7 Signaling Pathway in Immune Thrombocytopenia

Selective Death of Leukemia Initiating Cells Induced By Deferasirox

Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia

Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Microrna-17~92 Cluster Upregulates NF-KB Activity Via Suppressing Multiple NF-KB Negative Regulators Mediating Ubiquitination

Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only